Algeta ASA of Norway, which is developing a new treatment for hormone refractory prostate cancer called Alpharadin, has appointed Peter Harris as its chief medical officer.
News - Appointments
Clavis Pharma ASA of Norway, which has two cancer drugs in clinical development, has appointed Geir Christian Melen as chief executive officer, replacing Tom Pike, who has been nominated as exe
Marc Jaeger of Luxembourg has been elected president of the Court of First Instance (CFI) of the European Communities effective 17 September 2007. His term runs until 31 August 2010.
Ablynx NV, a Belgian company that produces a novel class of therapeutic proteins based on single domain antibody fragments, has appointed Josefin-Beate Holz to the newly created position of chi
Bob Hartmayer will become Business Group Director of DSM Pharmaceutical Products on 1 January 2008. He is presently director of DSM Elastomers.
Jado Technologies of Dresden has appointed Charl van Zyl as its new chief executive officer, effective 4 September 2007.
John Hutchison has announced plans to leave his position as development director of Vernalis Plc to join another company in the life sciences sector.
Egalet A/S, a Danish company that has developed technology for the controlled release of drugs through gradual erosion of a tablet, said it has appointed Peter Nordkild as chief executive offic
TheraGenetics Ltd, which produces gene-based tests for establishing the likelihood of a patient responding to a drug or of experiencing side effects, has appointed Heiner Dreismann as chairman.
Probiodrug AG, a developer of small molecule inhibitors against inflammatory and neurodegenerative diseases, has appointed Hendrik Liebers as its chief financial officer, following a round of new f